[Evidence-based drug therapy for heart failure-an update].
Aktuelles zur evidenzbasierten medikamentösen Herzinsuffizienztherapie.
Comorbidity
Guidelines
Health care systems
Heart diseases
Mortality
Journal
Herz
ISSN: 1615-6692
Titre abrégé: Herz
Pays: Germany
ID NLM: 7801231
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
19
04
2019
accepted:
01
06
2019
revised:
31
05
2019
pubmed:
27
6
2019
medline:
15
12
2020
entrez:
26
6
2019
Statut:
ppublish
Résumé
Chronic heart failure affects millions of people worldwide and is associated with high morbidity and mortality. Because of steadily increasing ageing populations and improved survival rates after myocardial infarction, the incidence of chronic heart failure is rising. As acute decompensated heart failure is one of the leading causes for hospitalization in Germany, heart failure imposes a huge economic burden on its health care system. Guideline directed therapy is important to improve prognosis. In the following, we give an overview about novel heart failure clinical trial results and point to important comorbidities.
Identifiants
pubmed: 31236606
doi: 10.1007/s00059-019-4827-2
pii: 10.1007/s00059-019-4827-2
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM